<DOC>
	<DOC>NCT00102141</DOC>
	<brief_summary>The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.</brief_summary>
	<brief_title>Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
	<criteria>Have hypertension Are currently taking antihypertensive medications Have had natural menopause at least 1 year prior to screening Must require hormone therapy in the opinion of the investigator</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>vasomotor symptoms</keyword>
	<keyword>essential hypertension</keyword>
</DOC>